Mahmoud, H., Tawfek, M., Yamani, E., Zaher, M. (2023). Dyslipidemia in patients with Multiple Sclerosis and its correlation with disease parameters. test, 4(3), 53-64. doi: 10.21608/ejmr.2022.113515.1177
Hesham Boshra Mahmoud; Mona Hussien Tawfek; Ehab Hassan Yamani; Marina Awad Zaher. "Dyslipidemia in patients with Multiple Sclerosis and its correlation with disease parameters". test, 4, 3, 2023, 53-64. doi: 10.21608/ejmr.2022.113515.1177
Mahmoud, H., Tawfek, M., Yamani, E., Zaher, M. (2023). 'Dyslipidemia in patients with Multiple Sclerosis and its correlation with disease parameters', test, 4(3), pp. 53-64. doi: 10.21608/ejmr.2022.113515.1177
Mahmoud, H., Tawfek, M., Yamani, E., Zaher, M. Dyslipidemia in patients with Multiple Sclerosis and its correlation with disease parameters. test, 2023; 4(3): 53-64. doi: 10.21608/ejmr.2022.113515.1177

Dyslipidemia in patients with Multiple Sclerosis and its correlation with disease parameters

Egyptian Journal of Medical Research
Volume 4, Issue 3, July 2023, Pages 53-64    PDF (539.21 K)
Document Type: Original Article
DOI: 10.21608/ejmr.2022.113515.1177
Authors
Hesham Boshra Mahmoud1; Mona Hussien Tawfek2; Ehab Hassan Yamani1; Marina Awad Zaher* 1
1Cardiology Department, Faculty of Medicine, Beni-Suef University, Egypt
2Neurology Department, Faculty of Medicine, Beni-Suef University, Egypt
Abstract
Background: Much interest was directed towards studying vascular complications in patients with multiple sclerosis (MS). However, the mechanisms of these complications are not well-understood. Objective: our work aimed to evaluate the risk of dyslipidemia in patients with MS and to correlate this risk with disease parameters. Methods: A case-control study included 50 patients with MS diagnosis and 50 age- and sex-matched healthy controls. The incidence of dyslipidemia was assessed in all participants by measuring serum lipid parameters in patients and controls. Results: Serum total cholesterol and triglycerides levels were significantly higher in MS, compared with controls, while HDL-cholesterol levels were significantly lower in MS patients, compared with controls. No significant correlation was found between serum lipids and disease duration or disability. Conclusion: MS patients had significantly higher serum levels of total cholesterol and triglycerides and significantly lower serum level of HDL-cholesterol.
Keywords
Dyslipidemia; cholesterol; triglycerides; Multiple sclerosis
References
  1. Fitzner D, Simons M. “Chronic progressive multiple sclerosis - pathogenesis of neurodegeneration and therapeutic strategies.”Curr. Neuropharmacol. 2010; 8:305–315.
  2. Harbo HF, Gold R, Tintore M. “Sex and gender issues in multiple sclerosis.”Ther. Adv. Neurol. Disord. 2013; 6:237–248.
  3. Siffrin V, Vogt J, Radbruch H, Nitsch R, Zipp F. Multiple sclerosis—candidate mechanisms underlying CNS atrophy. Trends in Neurosciences. 2010; 33 (4): 202–210.
  4. Manouchehrinia A, Tanasescu R, Tench CR, Constantinescu CS. Mortality in multiple sclerosis: meta-analysis of standardised mortality ratios. J. Neurol. Neurosurg. Psychiatry. 2016; 87:324–331.
  5. Christiansen CF, Christensen S, Farkas DK, Miret M, Sørensen HT, Pedersen L. Risk of arterial cardiovascular diseases in patients with multiple sclerosis. Neuroepidemiology. 2010; 35: 267–274.
  6. Salemi G, Gueli MC, Vitale F, et al. Blood lipids, homocysteine, stress factors, and vitamins in clinically stable multiple sclerosis patients. Lipids Health Dis. 2010; 18: 9-19.
  7. Khovidhunkit, W. et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res. 2004 ;45: 1169–1196.
  8. Lozovoy MA, Simão AN, Hohmann MS, Simão TN, Barbosa DS, Morimoto HK, Reiche EM, Cecchini R DI. Inflammatory biomarkers and oxidative stress measurements in patients with systemic lupus erythematosus with or without metabolic syndrome. Lupus. 2011;20(13):1356-1364.
  9. Villoslada P, Alonso C, Agirrezabal I, Kotelnikova E, Zubizarreta I, Pulido-Valdeolivas I, Saiz A, Comabella M, Montalban X, Villar L, Alvarez-Cermeño JC, Fernández O, Alvarez-Lafuente R, Arroyo R CA. Metabolomic signatures associated with disease severity in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2017; 4: e321.
  10. Soltow QA, Jones DP, Promislow DE . A network perspective on metabolism and aging. Integr Comp Biol. 2010;50:844–854.
  11. Penesova A, Vlcek M, Imrich R, Vernerova L, Marko A, Meskova M, Grunnerova L, Turcani P, Jezova D KB. Hyperinsulinemia in newly diagnosed patients with multiple sclerosis. Metab Brain Dis. 2015; 30, 895–901.
  12. Krauss R. M. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care. 2004; 27, 1496–1504.
  13. S Blumenfeld Kan, E Staun-Ram, D Golan AM. HDL-cholesterol elevation associated with fingolimod and dimethyl fumarate therapies in multiple sclerosis . Mult Scler J Exp Transl Clin. 2019; 5(4): 2055217319882720.
  14. Sholter DE, Armstrong PW. Adverse effects of corticosteroids on the cardiovascular system. Can J Cardiol 2000; 16: 505–511.
  15. Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Trab CJ. Diagnosis of multiple sclerosis. 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2): 162–173.
  16. Kurtzke, J.F. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology.1983; 33: 1444–1452.
  17. Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF WD. ESC/EAS Guidelines for the management of dyslipidaemias. European Heart Journal. 2011; 32: 1769–1818.
  18. Goodin, D. S. The epidemiology of multiple sclerosis: insights to disease pathogenesis. Handb. Clin. Neurol. 2014; 122: 231–266.
  19. Kang, J. H., Chen, Y. H. & Lin, H. C. Comorbidities amongst patients with multiple sclerosis: a population-based controlled study. Eur. J. Neurol. 2010; 17: 1215–1219.
  20. Lalmohamed A, Bazelier MT, Van Staa TP, Uitdehaag BM, Leufkens HG, De Boer A DVF. Causes of death in patients with multiple sclerosis and matched referent subjects. Eur. J. Neurol. 2012; 19: 1007–1014.
  21. Rasha Hassan Soliman, Hanan Mohamed Farhan, Mohamed Hegazy, Mohammed Ibrahim Oraby, Shaimaa Hossam Kamel AH. Impact of insulin resistance and metabolic syndrome on disability in patients with multiple sclerosis. The Egyptian Journal of Neurology, Psychiatry and Neurosurgery. 2020; 56.
  22. Oliveira SR, Simão AN, Kallaur AP, de Almeida ER, Morimoto HK, Lopes J, Dichi I, Kaimen-Maciel DR RE. Disability in patients with multiple sclerosis: Influence of insulin resistance, adiposity, and oxidative stress. Nutrition. 2014; 30(3):268-273.
  23. Slawta JN1, McCubbin JA, Wilcox AR, Fox SD, Nalle DJ, Anderson. Coronary heart disease risk between active and inactive women with multiple sclerosis. Medicine and Science in Sports and Exercise. 2002;34(6):905-912.
  24. Shao B, Tang C, Sinha A, Mayer PS, Davenport GD, Brot N, Oda MN, Zhao XQ HJ. Humans with atherosclerosis have impaired ABCA1 cholesterol efflux and enhanced high-density lipoprotein oxidation by myeloperoxidase. Circulation research. 2014; 114: 1733–1742.
  25. Çomoǧlu, S. & Yardimci, S. & Okçu, Z. Body Fat Distribution and Plasma Lipid Profiles of Patients with Multiple Sclerosis. Turkish Journal of Medical Sciences. 2004; 34: 43-48.
  26. Navarro R. Segura. Plasma lipids and their fatty acid composition in multiple sclerosis. Neurologica. 1988; 78(2):152-157.
  27. Tettey P, Simpson S Jr, Taylor B, Blizzard L, Ponsonby AL, Dwyer T, Kostner K van der MI. An adverse lipid profile is associated with disability and progression in disability, in people with MS. Multiple Sclerosis Journal. 2014;20(13):1737-1744.
  28. Weinstock-Guttman B, Zivadinov R, Mahfooz N, Carl E, Drake A, Schneider J, Teter B, Hussein S, Mehta B, Weiskopf M, Durfee J, Bergsland N RM. Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosis. J Neuroinflammation. 2011; 8: 127.
  29. Chataway J, Schuerer N, Alsanousi A, et al. Effect of high-dose simvastatin on brain atrophyand disability in secondary progressive multiplesclerosis (MS-STAT): a randomised,placebo-controlled, phase 2 trial.Lancet. 2014;383(9936):2213-2221.
 

Statistics
Article View: 323
PDF Download: 294